Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma

BACKGROUND: Chondrosarcoma is a common form of malignant bone tumor with limited treatment options. Approximately half of chondrosarcomas harbor gain-of-function mutations in isocitrate dehydrogenase (IDH), and mutant IDH produces 2-hydroxyglutarate (2-HG), which is an oncometabolite that contribute...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagawa, Makoto, Yamaguchi, Masayuki, Endo, Makoto, Machida, Yukino, Hattori, Ayuna, Tanzawa, Fumie, Tsutsumi, Shinji, Kitabayashi, Issay, Kawai, Akira, Nakatani, Fumihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048072/
https://www.ncbi.nlm.nih.gov/pubmed/35493690
http://dx.doi.org/10.1016/j.jbo.2022.100430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048072/
https://www.ncbi.nlm.nih.gov/pubmed/35493690
http://dx.doi.org/10.1016/j.jbo.2022.100430

Ejemplares similares